Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) shares fell 9.3% during trading on Tuesday. The company traded as low as $2.45 and last traded at $2.45. 1,680 shares were traded during trading, a decline of 68% from the average session volume of 5,237 shares. The stock had previously closed at $2.70.
Oculis Stock Performance
The company’s 50 day moving average is $4.02 and its 200-day moving average is $8.58.
About Oculis
Oculis is a global biopharmaceutical company focused on developing treatments for eye diseases. The company uses proprietary topical ophthalmic drug-delivery technologies designed to deliver therapies to the eye without injections, with the goal of addressing conditions that can cause vision loss and other significant impairments.
Its pipeline includes investigational treatments for retinal diseases, ocular surface disorders and neuro-ophthalmic conditions. Key programs have included OCS-01, a topical dexamethasone formulation being developed for diabetic macular edema, and licaminlimab, an anti-tumor necrosis factor therapy under evaluation for dry eye disease.
Read More
- Five stocks we like better than Oculis
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
